Anhui Provincial Hospital

Company snapshot

Anhui Provincial Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hepatocellular Carcinoma, Acute Lymphoblastic Leukemia. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1), phase 1 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Anhui Provincial Hospital. Not investment advice.

• What is Anhui Provincial Hospital?

  Anhui Provincial Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hepatocellular Carcinoma, Acute Lymphoblastic Leukemia. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public

• Is Anhui Provincial Hospital publicly traded?

  Anhui Provincial Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Anhui Provincial Hospital develop or market?

  We link 5 drug profile(s) where Anhui Provincial Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/anhui-provincial-hospital#company-drugs.

• What are the latest developments for Anhui Provincial Hospital?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Anhui Provincial Hospital focus on?

  Anhui Provincial Hospital focuses on Hepatocellular Carcinoma, Acute Lymphoblastic Leukemia based on our analysis of their pipeline programs and drug development activities.